Dr Carole Helissey
- Spécialité
- Oncologue médical, expert poumon, rein, vessie et prostate - innovations thérapeutiques et recherche clinique, de la phase i à la phase iii
- Hôpital
- Hôpital Paris Saint Joseph
- Derniers articles
-
- [How to prevent and manage PARP inhibitor-related hematological toxicities in prostate cancer?]. (9 juil. 2026)
- Home-based supervised exercise on metastatic cancer patients receiving oral targeted therapy: the AFSOS-Unicancer QUALIOR randomized phase 2 study. (17 janv. 2026)
- Gastrointestinal metastasis in prostate cancer and therapeutic implications: A case report. (15 oct. 2025)
- Prevention and management of PARP inhibitor-related haematological toxicities in prostate cancer: French expert opinion using the Delphi method. (13 sept. 2025)
- Evaluation of the Safety, Pharmacokinetics, and Antitumor Activity of Tusamitamab Ravtansine in Patients With Nonsquamous NSCLC With High or Moderate Expression of Carcinoembryonic Antigen-Related Cell Adhesion Molecule 5. (15 mai 2025)